Download the white paper to learn more.
Bringing an API from early development to commercial manufacturing is increasingly complex, requiring deeper process understanding, stronger control and alignment with evolving regulatory expectations. This whitepaper explores how multivariate process analysis can transform drug substance development by moving beyond one-variable-at-a-time approaches to a more data-rich, risk-based framework.
Through practical guidance and real-world case studies, the paper shows how multivariate tools, grounded in Design of Experiments and Quality by Design, help teams map process parameters, identify critical variables and define robust operating ranges.
Key takeaways include:
- Faster, more informed decision-making through evaluation of multiple process variables at once
- Improved process understanding and clearer identification of critical parameters and interactions
- Effective de-risking through early data generation and establishment of defined operational ranges
- Greater scalability from early-phase development through commercial manufacturing
- Stronger alignment with regulatory expectations for risk-based, knowledge-driven development
With step-by-step methodologies and case studies, this resource highlights how even complex or time-constrained programs can benefit from accessible multivariate strategies, offering a compelling path to modernize API development and unlock deeper process insight.
Offered Free by: Eurofins CDMO Alphora
See All Resources from: Eurofins CDMO Alphora
